Quintiles and Biogen Idec Announce 5-Year Clinical Development Agreement

Quintiles and Biogen Idec have entered a five-year collaboration that is intended to increase clinical trial efficiency, transparency, quality, innovation and operational excellence. Under the agreement, a dedicated team from Quintiles will work with Biogen Idec on the design, planning and execution of Biogen Idec’s Phase II-IV studies and select phase I studies. In addition, Biogen Idec will leverage Quintiles’ technology and systems across its growing portfolio.

Read the full release.